Overview
Sponsor-declared trial summary
Phase
Human pharmacology (Phase I) - First administration to humans
Status
Authorised, recruitment pending
Participants planned
15
Countries
1
Sites
1
Glioblastoma
Key facts
- Sponsor
- Ygion Biomedical GmbH
- Participant type
- Patients
- Age range
- 18-64 years, 65+ years
- Gender
- Male and Female
- Therapeutic area
- Diseases [C] - Neoplasms [C04]
- Decision date (initial)
- 2026-06-29
- Transition trial
- No
- Low-intervention
- No
- Rare-disease indication
- No
- Vulnerable population
- Yes
External identifiers
- EU CT number
- 2025-524299-44-00
- WHO UTN
- U1111-1330-5924
Trial design
CTIS Part I — objectives, methods, condition coding
Conditions and MedDRA coding
Glioblastoma
| Version | Level | Code | Term | System organ class |
|---|---|---|---|---|
| 20.0 | PT | 10018336 | Glioblastoma | 100000004864 |
Sponsors and contacts
Sponsor organisations, regulatory contacts, third parties
Ygion Biomedical GmbH
- Sponsor organisation
- Ygion Biomedical GmbH
- Address
- Campus Biocenter 5, U-Bahn Station Wien-Mitte Landstrasse 0, Landstrasse U-Bahn Station Wien-Mitte Landstrasse 0 Landstrasse
- City
- Vienna
- Postcode
- 1030
- Country
- Austria
Scientific contact point
- Organisation
- Ygion Biomedical GmbH
- Contact name
- Clinical Trial Division
Public contact point
- Organisation
- Ygion Biomedical GmbH
- Contact name
- Clinical Trial Division
Locations
1 EU/EEA country · 1 investigational sites
By country
| Country | MS status | Planned subjects | Sites |
|---|---|---|---|
| Austria | Authorised, recruitment pending | 15 | 1 |
| Rest of world | — | 0 | — |
Investigational sites
Application history
1 submissions — initial application plus substantial / non-substantial modifications
| # | Type | Code | Submitted | Reference MS | Conclusion | Decision date |
|---|---|---|---|---|---|---|
| 1 | INITIAL | IN | 2026-03-05 | Austria | Acceptable 2026-06-22
|
2026-06-29 |